(Q30372164)

21 June 2017

1 reference

title

Advances in the development of influenza virus vaccines. (English)

1 reference

Erratum: Advances in the development of influenza virus vaccines

21 June 2017

0 references

corrigendum / erratum

1 reference

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/NRD4595

author

Peter Palese

series ordinal

2

1 reference

21 June 2017

Florian Krammer

1

0 references

publication date

1 March 2015

1 reference

Nature Reviews Drug Discovery

21 June 2017

published in

1 reference

21 June 2017

volume

14

1 reference

21 June 2017

issue

3

1 reference

21 June 2017

page(s)

167-182

1 reference

The annual production cycle for influenza vaccine

21 June 2017

cites work

1 reference

Influenza: old and new threats

31 March 2020

1 reference

Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic

31 March 2020

1 reference

Why do influenza virus subtypes die out? A hypothesis

31 March 2020

1 reference

Universal influenza virus vaccines: need for clinical trials

31 March 2020

1 reference

Protective Effect of Vaccination Against Induced Influenza A

31 March 2020

1 reference

PROTECTIVE EFFECT OF VACCINATION AGAINST INDUCED INFLUENZA B.

31 March 2020

1 reference

Importance of antigenic composition of influenza virus vaccine in protecting against the natural disease; observations during the winter of 1947-1948.

31 March 2020

1 reference

Reactogenicity and Immunogenicity of Bivalent Influenza A and Monovalent Influenza B Virus Vaccines in High-Risk Children

31 March 2020

1 reference

Adaptation and Growth Characteristics of Influenza Virus at 25° C

31 March 2020

1 reference

Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial

31 March 2020

1 reference

Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis

31 March 2020

1 reference

Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial

31 March 2020

1 reference

Effect of influenza vaccination in the first trimester of pregnancy

31 March 2020

1 reference

Cochrane re-arranged: support for policies to vaccinate elderly people against influenza

31 March 2020

1 reference

Influenza vaccine effectiveness in the community and the household

31 March 2020

1 reference

Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study

31 March 2020

1 reference

A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity

31 March 2020

1 reference

High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season

31 March 2020

1 reference

Efficacy of high-dose versus standard-dose influenza vaccine in older adults

31 March 2020

1 reference

The history of MF59(®) adjuvant: a phoenix that arose from the ashes

31 March 2020

1 reference

AS03-adjuvanted influenza vaccine in elderly people

31 March 2020

1 reference

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial

31 March 2020

1 reference

Vaccine for prevention of mild and moderate-to-severe influenza in children

31 March 2020

1 reference

Vaccine for Prevention of Influenza in Children

31 March 2020

1 reference

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination

31 March 2020

1 reference

Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

31 March 2020

1 reference

Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus

31 March 2020

1 reference

Evolutionary dynamics and emergence of panzootic H5N1 influenza viruses.

31 March 2020

1 reference

Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses

31 March 2020

1 reference

Seroevidence for H5N1 influenza infections in humans: meta-analysis

31 March 2020

1 reference

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

31 March 2020

1 reference

Human infection with a novel avian-origin influenza A (H7N9) virus

31 March 2020

1 reference

Human infection with avian influenza A H6N1 virus: an epidemiological analysis

31 March 2020

1 reference

Avian influenza A H10N8--a virus on the verge?

31 March 2020

1 reference

Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study.

31 March 2020

1 reference

Highly pathogenic avian influenza A(H7N3) virus in poultry workers, Mexico, 2012.

31 March 2020

1 reference

Emergence of fatal avian influenza in New England harbor seals

31 March 2020

1 reference

Avian influenza A(H10N7) virus involvement in mass mortality of harbour seals (Phoca vitulina) in Sweden, March through October 2014.

31 March 2020

2 references

31 March 2020

12 December 2020

Avian influenza outbreak in Yorkshire: strain identified as H5N8

1 reference

The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines

31 March 2020

1 reference

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine

31 March 2020

1 reference

Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans

31 March 2020

1 reference

A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine

31 March 2020

1 reference

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

31 March 2020

1 reference

31 March 2020

H5N1 vaccines in humans

1 reference

Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial

31 March 2020

1 reference

Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial

31 March 2020

1 reference

An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans

31 March 2020

1 reference

Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.

31 March 2020

1 reference

Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans

31 March 2020

1 reference

Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.

31 March 2020

1 reference

A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.

31 March 2020

1 reference

An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults

31 March 2020

1 reference

An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults

31 March 2020

1 reference

Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.

31 March 2020

1 reference

H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus

31 March 2020

1 reference

Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).

31 March 2020

1 reference

African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates.

31 March 2020

1 reference

A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys

31 March 2020

1 reference

Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza

31 March 2020

1 reference

Role of receptor binding specificity in influenza A virus transmission and pathogenesis

31 March 2020

1 reference

Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect

31 March 2020

1 reference

A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.

31 March 2020

1 reference

Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.

31 March 2020

1 reference

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

31 March 2020

1 reference

Recombinant protein vaccines produced in insect cells

31 March 2020

1 reference

Alternative influenza vaccines made by insect cells

31 March 2020

1 reference

The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants.

31 March 2020

1 reference

An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli

31 March 2020

1 reference

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response

31 March 2020

1 reference

Immunoprotection against influenza virus H9N2 by the oral administration of recombinant Lactobacillus plantarumNC8 expressing hemagglutinin in BALB/c mice

31 March 2020

1 reference

Vaccination against influenza with recombinant hemagglutinin expressed by Schizochytrium sp. confers protective immunity

31 March 2020

1 reference

Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin

31 March 2020

1 reference

Recombinant haemagglutinin protein of highly pathogenic avian influenza A (H5N1) virus expressed in Pichia pastoris elicits a neutralizing antibody response in mice

31 March 2020

1 reference

Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens

31 March 2020

1 reference

The Receptor-Binding Domain of Influenza Virus Hemagglutinin Produced in Escherichia coli Folds into Its Native, Immunogenic Structure

31 March 2020

1 reference

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans

31 March 2020

1 reference

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

31 March 2020

1 reference

Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice.

31 March 2020

1 reference

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

31 March 2020

1 reference

One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.

31 March 2020

1 reference

Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity

31 March 2020

1 reference

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

31 March 2020

1 reference

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

31 March 2020

1 reference

A recombinant viruslike particle influenza A (H7N9) vaccine

31 March 2020

1 reference

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

31 March 2020

1 reference

Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans

31 March 2020

1 reference

Virus-vectored influenza virus vaccines

31 March 2020

1 reference

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

31 March 2020

1 reference

Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model

31 March 2020

1 reference

Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases

31 March 2020

1 reference

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

31 March 2020

1 reference

A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model

31 March 2020

1 reference

Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccine.

31 March 2020

1 reference

Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.

31 March 2020

1 reference

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

31 March 2020

1 reference

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

31 March 2020

1 reference

H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination

31 March 2020

1 reference

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

31 March 2020

1 reference

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

31 March 2020

1 reference

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

31 March 2020

1 reference

Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies

31 March 2020

1 reference

Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses

31 March 2020

1 reference

A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin

31 March 2020

1 reference

Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses

31 March 2020

1 reference

Cross-neutralization of influenza A viruses mediated by a single antibody loop

31 March 2020

1 reference

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin

31 March 2020

1 reference

Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5.

31 March 2020

1 reference

Antibody recognition of a highly conserved influenza virus epitope

31 March 2020

1 reference

A common solution to group 2 influenza virus neutralization

31 March 2020

1 reference

A highly conserved neutralizing epitope on group 2 influenza A viruses

31 March 2020

1 reference

Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin

31 March 2020

1 reference

A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo

31 March 2020

1 reference

Highly Conserved Protective Epitopes on Influenza B Viruses

31 March 2020

1 reference

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

31 March 2020

1 reference

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies

31 March 2020

1 reference

A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates

31 March 2020

1 reference

Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies

31 March 2020

1 reference

Mechanisms of hemagglutinin targeted influenza virus neutralization

31 March 2020

1 reference

Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies

31 March 2020

1 reference

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo

31 March 2020

1 reference

Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques

31 March 2020

1 reference

Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies

31 March 2020

1 reference

Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine

31 March 2020

1 reference

H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice

31 March 2020

1 reference

Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice

31 March 2020

1 reference

Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

31 March 2020

1 reference

Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses

31 March 2020

1 reference

Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem

31 March 2020

1 reference

1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans

31 March 2020

1 reference

B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination

31 March 2020

1 reference

Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.

31 March 2020

1 reference

Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories

31 March 2020

1 reference

Immune history shapes specificity of pandemic H1N1 influenza antibody responses.

31 March 2020

1 reference

In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen

31 March 2020

1 reference

A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains.

31 March 2020

1 reference

Universal anti-neuraminidase antibody inhibiting all influenza A subtypes

31 March 2020

1 reference

Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection.

31 March 2020

1 reference

Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses

31 March 2020

1 reference

Glycans on influenza hemagglutinin affect receptor binding and immune response

31 March 2020

1 reference

Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections.

31 March 2020

1 reference

Biogenesis of influenza a virus hemagglutinin cross-protective stem epitopes

31 March 2020

1 reference

Comparative glycomics analysis of influenza Hemagglutinin (H5N1) produced in vaccine relevant cell platforms.

31 March 2020

1 reference

Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain

31 March 2020

1 reference

Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles

31 March 2020

1 reference

Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses

31 March 2020

1 reference

Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants

31 March 2020

1 reference

The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region

31 March 2020

1 reference

Influenza virus vaccine based on the conserved hemagglutinin stalk domain

31 March 2020

1 reference

Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge

31 March 2020

1 reference

Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge

31 March 2020

1 reference

Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection

31 March 2020

1 reference

Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines

31 March 2020

1 reference

Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin

31 March 2020

1 reference

Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes

31 March 2020

1 reference

Influenza virus hemagglutinin stalk-based antibodies and vaccines

31 March 2020

1 reference

Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

31 March 2020

1 reference

Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies

31 March 2020

1 reference

H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge

31 March 2020

1 reference

Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.

31 March 2020

1 reference

Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies

31 March 2020

1 reference

Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin

31 March 2020

1 reference

Eliciting broadly protective antibody responses against influenza

31 March 2020

1 reference

Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development

31 March 2020

1 reference

Computationally optimized antigens to overcome influenza viral diversity

31 March 2020

1 reference

Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines

31 March 2020

1 reference

A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets

31 March 2020

1 reference

A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection

31 March 2020

1 reference

Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins

31 March 2020

1 reference

Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada

31 March 2020

1 reference

Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution

31 March 2020

1 reference

Stability of neuraminidase in inactivated influenza vaccines.

31 March 2020

1 reference

Induction of Partial Immunity to Influenza by a Neuraminidase-specific Vaccine

31 March 2020

1 reference

Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins

31 March 2020

1 reference

Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition

31 March 2020

1 reference

Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans

31 March 2020

1 reference

Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice

31 March 2020

1 reference

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

31 March 2020

1 reference

A universal influenza A vaccine based on the extracellular domain of the M2 protein

31 March 2020

1 reference

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

31 March 2020

1 reference

Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines

31 March 2020

1 reference

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

31 March 2020

1 reference

Universal influenza A vaccine: optimization of M2-based constructs.

31 March 2020

1 reference

In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran

31 March 2020

1 reference

Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.

31 March 2020

1 reference

Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza

31 March 2020

1 reference

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

31 March 2020

1 reference

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years

31 March 2020

1 reference

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

31 March 2020

1 reference

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine

31 March 2020

1 reference

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses

31 March 2020

1 reference

Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.

31 March 2020

1 reference

IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection

31 March 2020

1 reference

Protection against lethal influenza with a viral mimic

31 March 2020

1 reference

Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice

31 March 2020

1 reference

Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity

31 March 2020

1 reference

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes

31 March 2020

1 reference

Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.

31 March 2020

1 reference

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine

31 March 2020

1 reference

Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population

31 March 2020

1 reference

Cellular immune correlates of protection against symptomatic pandemic influenza.

31 March 2020

1 reference

Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells

31 March 2020

1 reference

Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus

31 March 2020

1 reference

Receptor mimicry by antibody F045–092 facilitates universal binding to the H3 subtype of influenza virus

31 March 2020

1 reference

The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site

31 March 2020

1 reference

GlyProt: in silico glycosylation of proteins

31 March 2020

1 reference

The structure and receptor binding properties of the 1918 influenza hemagglutinin

31 March 2020

1 reference

Structural Characterization of the 1918 Influenza Virus H1N1 Neuraminidase

31 March 2020

1 reference

Live attenuated influenza vaccine

31 March 2020

1 reference

12 December 2020

Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure

1 reference

12 December 2020

Rapid production of synthetic influenza vaccines.

1 reference

12 December 2020

A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

1 reference

12 December 2020

Notes from the field: Outbreak of influenza A (H3N2) virus among persons and swine at a county fair--Indiana, July 2012.

1 reference

12 December 2020

Broadly cross-reactive monoclonal antibodies against HA2 glycopeptide of Influenza A virus hemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin.

1 reference

12 December 2020

Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees

1 reference

12 December 2020

COMPARISONS OF SEROLOGIC AND FEBRILE RESPONSES IN HUMANS TO VACCINATION WITH INFLUENZA A VIRUSES OR THEIR HEMAGGLUTININS

1 reference

12 December 2020

Minimizing fucosylation in insect cell-derived glycoproteins reduces binding to IgE antibodies from the sera of patients with allergy

1 reference

12 December 2020

Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition

1 reference

12 December 2020

Two distinct regions of HA2 glycopolypeptide of influenza virus hemagglutinin elicit cross-protective immunity against influenza

1 reference

12 December 2020

Rescue of influenza A virus from recombinant DNA.

1 reference

12 December 2020

Inactivated and adjuvanted influenza vaccines.

1 reference

12 December 2020

The influenza programme of WHO.

1 reference

12 December 2020

Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly

1 reference

12 December 2020

Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4529

1 reference

21 June 2017

1 reference